Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

57.1%

4 terminated/withdrawn out of 7 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

250%

5 of 2 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Phase 2

1(14.3%)

Phase 3

1(14.3%)

7Total

Phase 1(5)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04501939Phase 2Active Not Recruiting

Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

Role: collaborator

NCT02776917Phase 1Completed

Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer

Role: collaborator

NCT03088878Phase 1Completed

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Role: lead

NCT02657005Phase 1Terminated

TK216 in Patients With Relapsed or Refractory Ewing Sarcoma

Role: lead

NCT05917470Phase 1Terminated

A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

Role: lead

NCT05588440Phase 1Terminated

A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Role: lead

NCT05431179Phase 3Withdrawn

A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Role: lead

All 7 trials loaded